JP2024522494A5 - - Google Patents
Info
- Publication number
- JP2024522494A5 JP2024522494A5 JP2023572751A JP2023572751A JP2024522494A5 JP 2024522494 A5 JP2024522494 A5 JP 2024522494A5 JP 2023572751 A JP2023572751 A JP 2023572751A JP 2023572751 A JP2023572751 A JP 2023572751A JP 2024522494 A5 JP2024522494 A5 JP 2024522494A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- compound according
- disorder
- prevention
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025051003A JP2025098157A (ja) | 2021-06-04 | 2025-03-26 | トリアジン誘導体およびがんの処置におけるその使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21177660.4 | 2021-06-04 | ||
| EP21177660 | 2021-06-04 | ||
| EP21188639 | 2021-07-30 | ||
| EP21188639.5 | 2021-07-30 | ||
| EP21215875.2 | 2021-12-20 | ||
| EP21215875 | 2021-12-20 | ||
| PCT/EP2022/064995 WO2022253936A1 (en) | 2021-06-04 | 2022-06-02 | Triazine derivatives and their use in the treatment of cancer. |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025051003A Division JP2025098157A (ja) | 2021-06-04 | 2025-03-26 | トリアジン誘導体およびがんの処置におけるその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024522494A JP2024522494A (ja) | 2024-06-21 |
| JP2024522494A5 true JP2024522494A5 (OSRAM) | 2025-04-03 |
| JP7705963B2 JP7705963B2 (ja) | 2025-07-10 |
Family
ID=82115763
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023572751A Active JP7705963B2 (ja) | 2021-06-04 | 2022-06-02 | トリアジン誘導体およびがんの処置におけるその使用 |
| JP2025051003A Pending JP2025098157A (ja) | 2021-06-04 | 2025-03-26 | トリアジン誘導体およびがんの処置におけるその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025051003A Pending JP2025098157A (ja) | 2021-06-04 | 2025-03-26 | トリアジン誘導体およびがんの処置におけるその使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20240132471A1 (OSRAM) |
| EP (1) | EP4347571B1 (OSRAM) |
| JP (2) | JP7705963B2 (OSRAM) |
| KR (1) | KR20240019083A (OSRAM) |
| AR (1) | AR126053A1 (OSRAM) |
| AU (1) | AU2022287224A1 (OSRAM) |
| BR (1) | BR112023025318A2 (OSRAM) |
| CA (1) | CA3216026A1 (OSRAM) |
| CL (1) | CL2023003491A1 (OSRAM) |
| CO (1) | CO2023016212A2 (OSRAM) |
| CR (1) | CR20230566A (OSRAM) |
| IL (1) | IL307201A (OSRAM) |
| MX (1) | MX2023013998A (OSRAM) |
| PE (1) | PE20240928A1 (OSRAM) |
| TW (1) | TW202313577A (OSRAM) |
| WO (1) | WO2022253936A1 (OSRAM) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| BR112023022451A2 (pt) * | 2021-04-28 | 2024-01-02 | Astellas Pharma Inc | Composto triazina substituído |
| BR112023025318A2 (pt) * | 2021-06-04 | 2024-02-27 | Hoffmann La Roche | Derivados de triazina e seu uso no tratamento do câncer |
| CA3246797A1 (en) * | 2022-01-07 | 2025-07-08 | Transthera Sciences (Nanjing) , Inc. | Nlrp3 inflammasome inhibitor and application thereof |
| US20260015353A1 (en) * | 2022-07-21 | 2026-01-15 | Hoffmann-La Roche Inc. | Novel compounds |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
| CN121045190A (zh) * | 2022-11-04 | 2025-12-02 | 药捷安康(南京)科技股份有限公司 | Nlrp3炎症小体抑制剂及其应用 |
| CR20250215A (es) * | 2022-12-07 | 2025-06-26 | Hoffmann La Roche | Compuestos novedosos como moduladores de la inhibición de nlrp3 |
| KR20250158072A (ko) * | 2023-03-20 | 2025-11-05 | 인실리코 메디신 아이피 리미티드 | Nlrp3 인플라마좀 억제제 및 이의 용도 |
| KR20250162889A (ko) * | 2023-03-23 | 2025-11-19 | 청두 제니타르 바이오메디컬 테크놀로지 컴퍼니 리미티드 | 트리아진계 화합물 및 이의 용도 |
| TW202448448A (zh) * | 2023-04-19 | 2024-12-16 | 瑞士商赫孚孟拉羅股份公司 | 新穎化合物 |
| CR20250409A (es) * | 2023-04-19 | 2025-10-30 | Hoffmann La Roche | Derivados de oxazolo[4,5-b]pirazina y oxazolo[4,5-b]piridina como inhibidores de nlpr3 para el tratamiento de, por ejemplo, enfermedades inflamatoria |
| EP4719599A1 (en) | 2023-06-02 | 2026-04-08 | Merck Sharp & Dohme LLC | 5,6 unsaturated bicyclic heterocyles useful as inhibitors of nod-like receptor protein 3 |
| CN121586712A (zh) * | 2023-07-28 | 2026-02-27 | 豪夫迈·罗氏有限公司 | 新颖化合物 |
| KR20250030934A (ko) * | 2023-08-25 | 2025-03-05 | 제일약품주식회사 | Nlrp3 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물 |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
| WO2025252772A1 (en) * | 2024-06-06 | 2025-12-11 | F. Hoffmann-La Roche Ag | Triazine derivatives |
| WO2026046981A1 (en) | 2024-08-28 | 2026-03-05 | F. Hoffmann-La Roche Ag | Solid forms of 5-[3-[[(3r)-1-ethyl-3-piperidyl]amino]-5-methyl-1,2,4-triazin-6-yl]-2,3- dihydrobenzofuran-4-ol |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102636383B1 (ko) * | 2017-08-04 | 2024-02-14 | 스카이호크 테라퓨틱스, 인코포레이티드 | 스플라이싱을 조절하는 방법 및 조성물 |
| TW201910316A (zh) | 2017-08-15 | 2019-03-16 | 愛爾蘭商英弗雷佐姆有限公司 | 新穎化合物 |
| PE20210050A1 (es) | 2017-11-09 | 2021-01-08 | Inflazome Ltd | Nuevos compuestos de sulfonamida carboxamida |
| AU2019243048A1 (en) * | 2018-03-27 | 2020-10-15 | Ptc Therapeutics, Inc. | Compounds for treating Huntington's disease |
| US12168012B2 (en) | 2018-07-25 | 2024-12-17 | Novartis Ag | NLRP3 inflammasome inhibitors |
| CN119320388A (zh) * | 2019-02-04 | 2025-01-17 | 斯基霍克疗法公司 | 用于调节剪接的方法和组合物 |
| UY38687A (es) | 2019-05-17 | 2023-05-15 | Novartis Ag | Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso |
| JP7843705B2 (ja) | 2020-01-22 | 2026-04-10 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｎｌｒｐ３モジュレーターとしてのスルホンイミドアミド化合物 |
| ES3064621T3 (en) | 2020-03-27 | 2026-04-27 | Tenvie Therapeutics Inc | Substituted pyridazine compound |
| US20240391895A1 (en) | 2020-12-25 | 2024-11-28 | Tuojie Biotech (Shanghai) Co., Ltd. | Pyridazine-containing compound and medicinal use thereof |
| WO2022166890A1 (zh) | 2021-02-08 | 2022-08-11 | 南京明德新药研发有限公司 | 取代的哒嗪苯酚类衍生物 |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| BR112023022451A2 (pt) | 2021-04-28 | 2024-01-02 | Astellas Pharma Inc | Composto triazina substituído |
| BR112023025318A2 (pt) * | 2021-06-04 | 2024-02-27 | Hoffmann La Roche | Derivados de triazina e seu uso no tratamento do câncer |
| US20240294542A1 (en) | 2021-06-05 | 2024-09-05 | Transthera Sciences (Nanjing), Inc. | Nlrp3 inflammasome inhibitor and application thereof |
| HRP20251513T1 (hr) | 2021-07-02 | 2026-01-02 | Astrazeneca Ab | Inhibitori inflamasoma nlrp3 |
| WO2023028536A1 (en) | 2021-08-25 | 2023-03-02 | Ptc Therapeutics, Inc. | 1,2,4-triazine derivatives useful as inhibitors of nlrp3 |
| WO2023066377A1 (zh) | 2021-10-22 | 2023-04-27 | 索智生物科技（浙江）有限公司 | 一种含氮化合物、其制备方法及应用 |
| CA3246797A1 (en) | 2022-01-07 | 2025-07-08 | Transthera Sciences (Nanjing) , Inc. | Nlrp3 inflammasome inhibitor and application thereof |
| IL315842A (en) | 2022-03-25 | 2024-11-01 | Ventus Therapeutics U S Inc | Pyrido-[4,3-D]pyridazine amine derivatives are useful as NLRP3 derivatives |
| TW202432551A (zh) | 2022-10-26 | 2024-08-16 | 日商安斯泰來製藥股份有限公司 | 稠環嗒嗪衍生物 |
| CN115621720A (zh) * | 2022-10-27 | 2023-01-17 | 永道射频技术股份有限公司 | 一种应用于rfid读写器的全息超材料阵列天线 |
| CN121045190A (zh) | 2022-11-04 | 2025-12-02 | 药捷安康(南京)科技股份有限公司 | Nlrp3炎症小体抑制剂及其应用 |
| JP2026503239A (ja) | 2022-12-28 | 2026-01-28 | アストラゼネカ・アクチエボラーグ | Ｎｌｒｐ３インフラマソーム阻害剤 |
| CN120435466A (zh) | 2023-02-17 | 2025-08-05 | 成都赜灵生物医药科技有限公司 | 六元氮杂环类化合物及其用途 |
-
2022
- 2022-06-02 BR BR112023025318A patent/BR112023025318A2/pt unknown
- 2022-06-02 IL IL307201A patent/IL307201A/en unknown
- 2022-06-02 EP EP22731614.8A patent/EP4347571B1/en active Active
- 2022-06-02 JP JP2023572751A patent/JP7705963B2/ja active Active
- 2022-06-02 MX MX2023013998A patent/MX2023013998A/es unknown
- 2022-06-02 KR KR1020237039328A patent/KR20240019083A/ko active Pending
- 2022-06-02 CR CR20230566A patent/CR20230566A/es unknown
- 2022-06-02 CA CA3216026A patent/CA3216026A1/en active Pending
- 2022-06-02 AR ARP220101456A patent/AR126053A1/es unknown
- 2022-06-02 TW TW111120574A patent/TW202313577A/zh unknown
- 2022-06-02 WO PCT/EP2022/064995 patent/WO2022253936A1/en not_active Ceased
- 2022-06-02 PE PE2023003133A patent/PE20240928A1/es unknown
- 2022-06-02 AU AU2022287224A patent/AU2022287224A1/en active Pending
-
2023
- 2023-11-23 CL CL2023003491A patent/CL2023003491A1/es unknown
- 2023-11-29 CO CONC2023/0016212A patent/CO2023016212A2/es unknown
- 2023-11-30 US US18/524,678 patent/US20240132471A1/en not_active Abandoned
-
2025
- 2025-02-25 US US19/063,141 patent/US12421209B2/en active Active
- 2025-03-26 JP JP2025051003A patent/JP2025098157A/ja active Pending
- 2025-05-16 US US19/210,925 patent/US20250276958A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022096662A5 (OSRAM) | ||
| JP2024540445A5 (OSRAM) | ||
| JP6505013B2 (ja) | スルファモイル−アリールアミド及びｂ型肝炎の治療のための薬剤としてのその使用 | |
| US20240374595A1 (en) | Substituted 1,1'-biphenyl compounds, analogues thereof, and methods using same | |
| JP5600685B2 (ja) | ジペプトイドプロドラッグおよびそれらの使用 | |
| JP2020532506A5 (OSRAM) | ||
| JP2020507589A5 (OSRAM) | ||
| JP2024517917A5 (OSRAM) | ||
| JP2023543059A5 (OSRAM) | ||
| JP2007524683A5 (OSRAM) | ||
| JP2019517455A5 (OSRAM) | ||
| JP2017537158A5 (OSRAM) | ||
| CN1794988B (zh) | 用于治疗血管渗透性过高疾病的组合物 | |
| JP2005515172A5 (OSRAM) | ||
| JP2022008860A5 (OSRAM) | ||
| IL196129A (en) | Human protein tyrosine phosphatase inhibitors, compositions comprising such compounds and uses thereof in the preparation of medicaments for regulating angiogenesis | |
| JP2013530179A5 (OSRAM) | ||
| JP2013544276A5 (OSRAM) | ||
| CN1378541A (zh) | c－JUN N－末端激酶(JNK)和其它蛋白激酶的抑制剂 | |
| JP2012512203A (ja) | アミノ酸エステルのプロドラッグおよびその使用 | |
| JP2019500387A5 (OSRAM) | ||
| US10117864B2 (en) | Substituted N-bicyclo-2-aryl-quinolin-4-carboxamides and use thereof | |
| JP2024518556A5 (OSRAM) | ||
| JP2016540811A5 (OSRAM) | ||
| JP2008517923A5 (OSRAM) |